The mice model market encompasses the global sector involved in the development, manufacturing, and distribution of laboratory mice used primarily for biomedical research, drug discovery, toxicology testing, and disease modeling. It primarily serves pharmaceutical and biotechnology companies, as well as academic and research institutes, to understand human disease mechanisms and evaluate the safety and efficacy of new therapies.
The global mice model market was valued at USD 1.53 billion in 2024 and reached USD 1.70 billion in 2025, and it is projected to reach USD 2.74 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
The mice model healthcare market is primarily driven by the escalating global prevalence of chronic diseases like cancer, rapid advancements in genetic engineering technologies such as CRISPR/Cas9, and a consistent demand for robust preclinical safety and efficacy data across the pharmaceutical and biotechnology sectors. However, market expansion is heavily restrained by complex ethical concerns and regulatory restrictions governing animal testing. Lucrative opportunities exist in the development of highly advanced, multigenic humanized mice models tailored for personalized medicine, targeted therapies, and immuno-oncology research. Despite these prospects, the industry faces key challenges, including mounting institutional and regulatory pressures to balance traditional animal studies with emerging alternative testing technologies while strictly adhering to evolving ethical guidelines.
The target customers for the mice model market primarily include pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions engaged in drug discovery, disease modeling, and preclinical trials. These institutional buyers require reliable, genetically stable, and physiologically versatile animal models, with a strong demand for specialized, genetically engineered or humanized mice that can accurately replicate human disease mechanisms, particularly in high-acuity areas like oncology, immunology, and neuroscience. Customers highly prefer advanced technologies like CRISPR/Cas9 that compress model-generation timelines, alongside comprehensive colony management services such as breeding, cryopreservation, and genetic testing to maintain health and compliance standards. Their purchasing behavior is heavily driven by expanding corporate and government R&D expenditures, a rising industrial focus on personalized medicine and targeted therapies, and the necessity to adhere to strict regulatory testing requirements before clinical drug approval.
Market entry, expansion, and profitability in the mice model market are heavily shaped by a shifting mix of regulatory, technological, and economic factors. Regulators and ethical oversight bodies enforce strict guidelines regarding animal research and cruelty, which ensures compliance and builds researcher confidence but can also act as a significant constraint that limits the market’s growth rate. Technologically, the industry is being rapidly disrupted by groundbreaking advancements in genetic engineering, most notably CRISPR/Cas9, which compresses model-generation timelines and lowers costs, alongside the integration of artificial intelligence for predictive analysis and the development of highly advanced humanized models. Economically, while robust global healthcare expenditure, massive pharmaceutical R&D investments, and substantial government and private research funding fuel sustained market growth, adoption in emerging regions remains gradual due to cost sensitivity.
The mice model market is being rapidly reshaped by a growing emphasis on precision medicine and personalized oncology solutions, driving high demand for complex, humanized, and genetically engineered models tailored to specific therapeutic areas. Advanced gene-editing technologies, most notably CRISPR/Cas9, are significantly disrupting the landscape by enabling precise, disease-specific modeling while compressing model-generation timelines and lowering costs. Furthermore, the market is experiencing an accelerating shift toward the integration of stem cell-based approaches, artificial intelligence to improve model efficacy, and the expansion of mouse clinical trials (MCTs) using patient-derived xenograft (PDX) models to better mimic human conditions. These trends are evolving at a swift pace, highlighted by the CRISPR/Cas9 technology segment advancing at a projected 13.60% CAGR and genetically engineered mice expanding at a 9.84% CAGR through 2031.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
Technological innovations disrupting the mice model healthcare market are centered on advanced genetic engineering, artificial intelligence, and translational modeling accuracy. The industry is witnessing significant traction in the adoption of CRISPR/Cas9 gene-editing technology, which serves as a highly disruptive tool by compressing model-generation timelines, lowering costs, and enabling precise knockout, knock-in, and multiplex editing for polygenic constructs. Concurrently, the development of advanced humanized mouse models is gaining rapid momentum to better replicate human biology, investigate complex disease mechanisms, and enhance the predictive validity of preclinical drug and oncology research. Furthermore, the integration of AI and machine learning platforms is increasingly utilized to enhance predictive modeling, improve study outcomes, and streamline high-throughput phenotyping for accelerated drug screening. Other notable advancements include pronuclear microinjection methods that facilitate precise delivery of genetic materials for transgenic modifications and complex gene function studies.
I do not have enough information in the provided document context to determine which trends represent short-term hype versus long-term structural shifts for the Mice Model Healthcare Market.
Source:https://www.marketsandmarkets.com/Market-Reports/mice-model-market-1308.html
